Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bewintinib
- Development stage
- Unknown
- Lead developer
- Hangzhou Guangliang Biomedical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bewintinib (HDM3002) is a potent and selective small-molecule inhibitor of Janus kinase 2 (JAK2), currently under development by Hangzhou Huadong Medicine Group Biopharmaceutical Co., Ltd. It is primarily being investigated for the treatment of myelofibrosis, a rare bone marrow cancer characterized by excessive scar tissue formation and dysregulated blood cell production. By inhibiting the JAK-STAT signaling pathway, which is often overactive in myeloproliferative neoplasms due to mutations such as JAK2V617F, bewintinib aims to reduce splenomegaly and improve constitutional symptoms in affected patients. The drug is designed to offer a favorable safety and efficacy profile compared to existing JAK inhibitors by specifically targeting the JAK2 isoform.
- Other names
- bewintinib
02
Targets
Beyond the preview
Go deeper on bewintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bewintinib.